Andrea Breglia1,2,3, Grazia Maria Virzì1,2, Silvia Pastori1,2, Alessandra Brocca1,2,4, Massimo de Cal1,2, Chiara Bolin5, Giorgio Vescovo5,6, Claudio Ronco1,2. 1. Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy. 2. IRRIV - International Renal Research Institute Vicenza, Vicenza, Italy. 3. Department of Internal Medicine, University of Trieste, Trieste, Italy. 4. Department of Medicine DIMED, University of Padua Medical School, Padua, Italy. 5. Internal Medicine, San Bortolo Hospital, Vicenza, Italy. 6. Internal Medicine Unit, Sant'Antonio Hospital, Padua, Italy.
Abstract
BACKGROUND: Cardiorenal syndrome type 1 (CRS type 1) is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Its pathophysiology is complex and not completely understood. In this study, we examined the role of apoptosis and the caspase pathways involved. MATERIAL AND METHODS: We enrolled 40 acute heart failure (AHF) patients, 11 of whom developed AKI characterizing CRS type 1. We exposed the human cell line U937 to plasma from the CRS type 1 and AHF groups and then we evaluated apoptotic activity by annexin-V evaluation, determination of caspase-3, -8 and -9 levels, and BAX, BAD, and FAS gene expression. RESULTS: We observed significant upregulation of apoptosis in monocytes exposed to CRS type 1 plasma compared to AHF, with increased levels of caspase-3 (p < 0.01), caspase-9 (p < 0.01), and caspase-8 (p < 0.03) showing activation of both intrinsic and extrinsic pathways. Furthermore, monocytes exposed to CRS type 1 plasma had increased gene expression of BAX and BAD (intrinsic pathways) (p = 0.010 for both). Furthermore, strong significant correlations between the caspase-9 levels and BAD and BAX gene expression were observed (Spearman ρ = - 0.76, p = 0.011, and ρ = - 0.72, p = 0.011). CONCLUSION: CRS type 1 induces dual apoptotic pathway activation in monocytes; the two pathways converged on caspase-3. Many factors may induce activation of both intrinsic and extrinsic apoptotic pathways in CRS type 1 patients, such as upregulation of proinflammatory cytokines and hypoxia/ischemia. Further investigations are necessary to corroborate the present findings, and to better understand the pathophysiological mechanism and consequent therapeutic and prognostic implications for CRS type 1.
BACKGROUND:Cardiorenal syndrome type 1 (CRS type 1) is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Its pathophysiology is complex and not completely understood. In this study, we examined the role of apoptosis and the caspase pathways involved. MATERIAL AND METHODS: We enrolled 40 acute heart failure (AHF) patients, 11 of whom developed AKI characterizing CRS type 1. We exposed the human cell line U937 to plasma from the CRS type 1 and AHF groups and then we evaluated apoptotic activity by annexin-V evaluation, determination of caspase-3, -8 and -9 levels, and BAX, BAD, and FAS gene expression. RESULTS: We observed significant upregulation of apoptosis in monocytes exposed to CRS type 1 plasma compared to AHF, with increased levels of caspase-3 (p < 0.01), caspase-9 (p < 0.01), and caspase-8 (p < 0.03) showing activation of both intrinsic and extrinsic pathways. Furthermore, monocytes exposed to CRS type 1 plasma had increased gene expression of BAX and BAD (intrinsic pathways) (p = 0.010 for both). Furthermore, strong significant correlations between the caspase-9 levels and BAD and BAX gene expression were observed (Spearman ρ = - 0.76, p = 0.011, and ρ = - 0.72, p = 0.011). CONCLUSION:CRS type 1 induces dual apoptotic pathway activation in monocytes; the two pathways converged on caspase-3. Many factors may induce activation of both intrinsic and extrinsic apoptotic pathways in CRS type 1 patients, such as upregulation of proinflammatory cytokines and hypoxia/ischemia. Further investigations are necessary to corroborate the present findings, and to better understand the pathophysiological mechanism and consequent therapeutic and prognostic implications for CRS type 1.
Authors: Silvia Pastori; Grazia Maria Virzì; Alessandra Brocca; Massimo de Cal; Anna Clementi; Giorgio Vescovo; Claudio Ronco Journal: Cardiorenal Med Date: 2015-02-11 Impact factor: 2.041
Authors: Grazia Maria Virzì; Rossella Torregrossa; Dinna N Cruz; Chang Y Chionh; Massimo de Cal; Sachin S Soni; Massimo Dominici; Giorgio Vescovo; Mitchell H Rosner; Claudio Ronco Journal: Cardiorenal Med Date: 2012-01-20 Impact factor: 2.041
Authors: Michael Haase; Christian Müller; Kevin Damman; Patrick T Murray; John A Kellum; Claudio Ronco; Peter A McCullough Journal: Contrib Nephrol Date: 2013-05-13 Impact factor: 1.580
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097